Molecular Imaging in Soft-tissue Sarcoma: Evolving Role of FDG PET.
Semin Nucl Med
; 54(3): 332-339, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38433024
ABSTRACT
Soft tissue sarcomas are a rare and heterogenous group of tumors that account for 2% of all cancer-related deaths. Molecular imaging with FDG PET can offer valuable metabolic information to help inform clinical management of soft tissue sarcomas that is unique and complementary to conventional diagnostic imaging techniques. FDG PET imaging often correlates with tumor grade, can help guide biopsy, and frequently detects additional sites of disease compared to conventional imaging in patients being considered for definitive or salvage therapy. Traditional size-based evaluation of treatment response is often inadequate in soft tissue sarcoma and changes in metabolic activity can add significant value to interim and end of treatment imaging for high-grade sarcomas. FDG PET can be used for detection of recurrence or malignant transformation and thus play a vital role in surveillance. This article reviews the evolving role of FDG PET in initial diagnosis, staging, treatment response assessment, and restaging. Further studies on the use of FDG PET in soft sarcoma are needed, particularly for rare histopathologic subtypes.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Sarcoma
/
Fluorodesoxiglucosa F18
/
Tomografía de Emisión de Positrones
Límite:
Humans
Idioma:
En
Revista:
Semin Nucl Med
Año:
2024
Tipo del documento:
Article
País de afiliación:
Canadá